ArticleImmuno-oncology technology2026
Corticosteroid exposure, tapering, and survival in immune-related colitis: a 10-year real-world melanoma cohort.
Article in Immuno-oncology technology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Immune-related diarrhoea and colitis (irC) is a common toxicity of immune checkpoint inhibitors (CPIs) in melanoma and frequently requires prolonged corticosteroid (CS) therapy. The impact of CS exposure on CPI efficacy remains uncertain, and evidence guiding tapering strategies and biological therapy is limited. The aim of this study was to evaluate the association between CS exposure (peak and cumulative) and survival in patients with melanoma having irC to identify predictors of prednisolone tapering failure and to describe treatment patterns in irC. Materials and methods: This 10-year retrospective cohort study included patients with melanoma from the Danish Metastatic Melanoma Database who developed irC during CPI therapy. Clinical characteristics, CS exposure, and treatment patterns were obtained through systematic medical record review. Associations between CS exposure and survival were assessed using multivariable Cox proportional hazards regression. Predictors of tapering failure were evaluated using multivariable logistic regression. Results: A total of 122 patients with irC requiring medical treatment were included. Higher cumulative CS exposure (>4000 mg) was associated with reduced overall survival (OS), whereas no significant association was observed at lower exposure levels. Peak CS dose was not independently associated with survival. Tapering failure occurred in 50% of patients. Anti-programmed cell death protein 1 monotherapy and early biological therapy were associated with a lower risk of tapering failure. Conclusions: Higher cumulative CS exposure was associated with reduced OS in patients with melanoma having irC, although this may reflect underlying disease severity and treatment responsiveness rather than a direct causal effect. Associations among biological therapy, treatment regimen, and tapering outcomes require confirmation. Prospective studies are warranted to clarify causal relationships and optimise treatment strategies.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.